Radiopharm Theranostics Ltd (RADX) Short term Debt (2024 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Short term Debt of $3.4 million for Q2 2025, down 45.86% year-over-year from $6.3 million in Q2 2024, and down 45.86% quarter-over-quarter from $6.3 million in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Short term Debt (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Short term Debt for 2 consecutive years, with $3.4 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Short term Debt fell 45.86% year-over-year to $3.4 million; the TTM figure through Jun 2025 stood at $3.4 million (down 45.86% YoY), while the FY2025 annual figure was $3.4 million, down 45.86% from the prior year.
- Short term Debt eased to $3.4 million in Q2 2025 per RADX's latest filing, from $6.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $6.3 million in Q2 2024 and bottomed at $3.4 million in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.42 Mn |
| Jun 30, 2024 | 6.32 Mn |